MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why GERN Stock dropped -2.30% Today — RQD Quant Desk Flash
$0.95 -2.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.94
Geron Corporation (GERN) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $607.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.94 (-0.60%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GERN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY GERN SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.23-4.9% Next Q
45
Q2 (-2Q)Grade D$1.17-4.3% Next Q
42
Q3 (-1Q)Grade D$1.12-15.2% Next Q
40
CurrentGrade D-$0.95-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GERN Turnaround Squeeze
While GERN currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.29) and Max Pain ($1.00) forces dealer call-delta covering toward $2.11.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GERN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GERN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GERN Stock dropped -2.30% Today — RQD Quant Desk Flash
Geron Corporation (GERN) dropped -2.30% to $0.95, trading at 9% of its 52-week range ($0.84 – $2.01). Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 9% of its 52-week range ($0.84 – $2.01) with RSI-14 at 22.1 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.95 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live GERN Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GERN)
- ✓Walkthrough of GERN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GERN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -38.31%▼ DESCENDING CHANNEL
2026-10-30O $0.93H $0.95L $0.86C $0.95VOL 18.81M
RES: $1.57SUP: $0.83SMA50: $1.29SMA200: $1.43
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GERN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on GERN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GERN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GERN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GERN)
Health Care Rank #744 of 1016
⚔️ NVCT vs GERN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GERN vs. NVCT, ZVRA, IRWD, CRMD)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Geron Corporation (GERN) ranks #744 by composite RQD confidence (37/100, grade D-) and #418 by equity capitalization ($607.9M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with GERN at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GERN
ACTIVE
Geron Corporation | D- | 37/100 | — | — | -20.2% | -2.30% | $607.9M | Benchmark Subject |
| NVCT Nuvectis Pharma Inc. | D- | 43/100 | — | — | -35.0% | +1.14% | $605.6M | /nvct-vs-gern → |
| ZVRA Zevra Therapeutics Inc. | D- | 40/100 | 7.4x | — | -32.3% | +0.49% | $615.2M | /zvra-vs-gern → |
| IRWD Ironwood Pharmaceuticals Inc. (Class A) | C+ | 69/100 | 24.9x | — | 85.0% | +0.28% | $598.2M | /irwd-vs-gern → |
| CRMD CorMedix Inc. | C | 62/100 | 3.7x | 88.5% | 45.5% | -6.83% | $595.5M | /crmd-vs-gern → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000886744In its most recent audited fiscal period (FY2025, filed 2025-12-31), Geron Corporation (GERN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$83.5M, operating cash flow of -$111.0M, and free cash flow of -$111.0M (+49.4% YoY). On the balance sheet, GERN closed FY2025 with $570.5M in total assets against $119.5M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$83.5M | -$111.0M | -$111.0M | $570.5M | $119.5M |
| FY2024 (FY) | 2024-12-31 | $0 | -$174.6M | -$218.6M | -$219.3M | $593.8M | $118.5M |
| FY2023 (FY) | 2023-12-31 | $237.0K | -$184.1M | -$167.7M | -$167.7M | — | — |
3. GERN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GERN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Geron Corporation (NASDAQ: GERN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $0.95 (-2.30% 1D, market cap $607.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GERN ranks #744 in composite RQD confidence.
How does GERN compare to NVCT and ZVRA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GERN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -20.2%. By comparison, NVCT (Nuvectis Pharma Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $605.6M) and ZVRA (Zevra Therapeutics Inc.) posts a D- grade (40/100 RQD, P/E 7.4x, ROIC -32.3%, cap $615.2M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GERN?
Per GERN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000886744), Geron Corporation generated $0 in revenue, -$83.5M in net income, and -$111.0M in free cash flow against $570.5M in total assets and $119.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GERN trading relative to its 50-day, 200-day, and 52-week technical levels?
GERN last traded at $0.95 (-2.30% on volume of 32,350,447 shares), positioning the stock -26.36% below its 50-day simple moving average ($1.29) and -33.57% below its 200-day simple moving average ($1.43). Across its 52-week range of $0.84 to $2.01, GERN sits at the 9.4% percentile with a 14-day RSI of 22.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $1.07).
GERN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GERN stock moving today?
Why GERN Stock dropped -2.30% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-20% return on capital) under elevated 10-year interest-rate pressure.